» Articles » PMID: 37578206

Bioethical Implications of Organ-on-a-chip on Modernizing Drug Development

Overview
Journal Artif Organs
Date 2023 Aug 14
PMID 37578206
Authors
Affiliations
Soon will be listed here.
Abstract

Organ-on-chips are three-dimensional microdevices that emulate the structure, functionality, and behavior of specific tissues or organs using human cells. Combining organoids with microfabricated fluidic channels and microelectronics, these systems offer a promising platform for studying disease mechanisms, drug responses, and tissue performance. By replicating the in vivo microenvironment, these devices can recreate complex cell interactions in controlled conditions and facilitate research in various fields, including drug toxicity and efficacy studies, biochemical analysis, and disease pathogenesis. Integrating human induced pluripotent stem cells further enhances their applicability, thereby enabling patient-specific disease modeling for precision medicine. Although challenges like economy-of-scale, multichip integration, and regulatory compliance exist, advances in this modular technology show promise for lowering drug development costs, improving reproducibility, and reducing the reliance on animal testing. The ethical landscape surrounding organ-on-chip usage presents both benefits and concerns. While these chips offer an alternative to animal testing and potential cost savings, they raise ethical considerations related to community engagement, informed consent, and the need for standardized guidelines. Ensuring public acceptance and involvement in decision-making is vital to address misinformation and mistrust. Furthermore, personalized medicine models using patient-derived cells demand careful consideration of potential ethical dilemmas, such as modeling physiological functions of fetuses or brains and determining the extent of protection for these models. To achieve the full potential of organ-on-a-chip models, collaboration between scientists, ethicists, and regulators is essential to fulfil the promise of transforming drug development, advancing personalized medicine, and contributing to a more ethical and efficient biomedical research landscape.

Citing Articles

Strategies for promoting neurovascularization in bone regeneration.

Li X, Zhao Y, Miao L, An Y, Wu F, Han J Mil Med Res. 2025; 12(1):9.

PMID: 40025573 PMC: 11874146. DOI: 10.1186/s40779-025-00596-1.


Recent Progress in PDMS-Based Microfluidics Toward Integrated Organ-on-a-Chip Biosensors and Personalized Medicine.

Alghannam F, Alayed M, Alfihed S, Sakr M, Almutairi D, Alshamrani N Biosensors (Basel). 2025; 15(2).

PMID: 39996978 PMC: 11852457. DOI: 10.3390/bios15020076.


Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review.

Berjaoui C, Kachouh C, Joumaa S, Hussein Ghayyad M, Abate Bekele B, Ajirenike R Ann Med Surg (Lond). 2024; 86(7):4053-4059.

PMID: 38989179 PMC: 11230822. DOI: 10.1097/MS9.0000000000002231.

References
1.
Jimenez-Tellez N, Vera C, Yildirim Z, Guevara J, Zhang T, Wu J . Generation of two iPSC lines from long QT syndrome patients carrying SNTA1 variants. Stem Cell Res. 2022; 66:103003. PMC: 10029814. DOI: 10.1016/j.scr.2022.103003. View

2.
Yildirim Z, Kojic A, Yan C, Wu M, Vagelos R, Wu J . Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients caused by heterozygous mutations in the HCN4 gene. Stem Cell Res. 2022; 65:102951. PMC: 9881502. DOI: 10.1016/j.scr.2022.102951. View

3.
Jeziorski J, Brandt R, Evans J, Campana W, Kalichman M, Thompson E . Brain organoids, consciousness, ethics and moral status. Semin Cell Dev Biol. 2022; 144:97-102. DOI: 10.1016/j.semcdb.2022.03.020. View

4.
Baptista L, Porrini C, Kronemberger G, Kelly D, Perrault C . 3D organ-on-a-chip: The convergence of microphysiological systems and organoids. Front Cell Dev Biol. 2022; 10:1043117. PMC: 9720174. DOI: 10.3389/fcell.2022.1043117. View

5.
Mourad O, Yee R, Li M, Nunes S . Modeling Heart Diseases on a Chip: Advantages and Future Opportunities. Circ Res. 2023; 132(4):483-497. DOI: 10.1161/CIRCRESAHA.122.321670. View